Back to Search
Start Over
Effectiveness and safety of secukinumab in patients with moderate-severe psoriasis: A multicenter real-life study
- Source :
- Dermatologic therapyREFERENCES. 33(6)
- Publication Year :
- 2020
-
Abstract
- This study assessed the effectiveness and safety of secukinumab in patients with moderate-severe psoriasis vulgaris in a real-world setting. A total of 120 patients (35.8% women; mean age 49.8 years) were enrolled. Mean PASI significantly decreased from 12.0 ± 6.6 at baseline to 4.7 ± 3.2 and 2.3 ± 4.0 at 3 and 12 months, respectively (P < .001). Patients with two or more lines of prior biological therapies had poorer persistence to therapy at 12 months (71%) vs those who were bio-naive (93%) or patients with only one prior failure with a biological agent (88%) (log-rank = 9.33; P = .009). Multivariate regression analysis showed that patients beyond the second line of treatment had an increased risk of discontinuing secukinumab (HR: 3.6; 95% CI 1.3-10.2), while those without comorbidities had a lower risk (HR: 0.31; 95% CI 0.1-0.8). Our study confirms the effectiveness and safety of secukinumab in a real-life setting for psoriatic disease.
- Subjects :
- Male
medicine.medical_specialty
Dermatology
Lower risk
Antibodies, Monoclonal, Humanized
Severity of Illness Index
030207 dermatology & venereal diseases
03 medical and health sciences
0302 clinical medicine
Second line
Internal medicine
Psoriasis
medicine
Humans
In patient
Severe psoriasis
business.industry
General Medicine
Middle Aged
medicine.disease
Increased risk
Treatment Outcome
030220 oncology & carcinogenesis
Secukinumab
Female
Life study
business
Subjects
Details
- ISSN :
- 15298019
- Volume :
- 33
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Dermatologic therapyREFERENCES
- Accession number :
- edsair.doi.dedup.....cc5d7b8fea3d9c1983fe23eb9eaf2e24